The treatment, rexmyelocel-T, is being developed to relieve leg pain at rest and heal leg ulcers. The treatment uses cells from bone marrow which are injected into the damaged blood vessel, where they restore existing blood vessels and create new blood vessels. By improving the blood flow in the limb, this treatment aims to improve the patient’s condition so that they do not require amputation.
Bimekizumab is in clinical development for moderate to severe chronic plaque psoriasis. Plaque psoriasis is a persistent, long lasting chronic inflammatory disease causing red, flaky and itchy patches of skin commonly appearing on the elbows, knees, scalp and lower back. Plaque psoriasis is an autoimmune disease, meaning that the immune cells which usually fight infection attack the body’s own tissues instead, in this case, the skin. Treatment is determined by the type and severity of psoriasis, and the area of skin affected, and may include a combination of topical, phototherapy and systemic (oral or injected) therapies.